ID   PP1R8_HUMAN             Reviewed;         351 AA.
AC   Q12972; Q5TEJ2; Q5TEJ4; Q5TIF2; Q6PKF6; Q9UBH1; Q9UBZ0;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   22-JUL-2015, entry version 149.
DE   RecName: Full=Nuclear inhibitor of protein phosphatase 1;
DE            Short=NIPP-1;
DE   AltName: Full=Protein phosphatase 1 regulatory inhibitor subunit 8;
DE   Includes:
DE     RecName: Full=Activator of RNA decay;
DE              EC=3.1.4.-;
DE     AltName: Full=ARD-1;
GN   Name=PPP1R8; Synonyms=ARD1, NIPP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM GAMMA).
RC   TISSUE=B-cell;
RX   PubMed=7524097; DOI=10.1073/pnas.91.22.10591;
RA   Wang M., Cohen S.N.;
RT   "ard-1: a human gene that reverses the effects of temperature-
RT   sensitive and deletion mutations in the Escherichia coli rne gene and
RT   encodes an activity producing RNase E-like cleavages.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:10591-10595(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS ALPHA AND BETA),
RP   ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.
RC   TISSUE=Parathyroid, and T-cell;
RX   PubMed=10103062; DOI=10.1046/j.1432-1327.1999.00272.x;
RA   Van Eynde A., Perez-Callejon E., Schoenmakers E., Jacquemin M.,
RA   Stalmans W., Bollen M.;
RT   "Organization and alternate splice products of the gene encoding
RT   nuclear inhibitor of protein phosphatase-1 (NIPP-1).";
RL   Eur. J. Biochem. 261:291-300(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA).
RC   TISSUE=Mammary cancer;
RA   Liu J.P., Yang Z., Li H.;
RT   "Complete cDNA sequence of NIPP-1 from human breast cancer cells.";
RL   Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA).
RC   TISSUE=Synovium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BETA), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 34-351 (ISOFORM ALPHA).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   TISSUE SPECIFICITY.
RX   PubMed=7499293; DOI=10.1074/jbc.270.47.28068;
RA   Van Eynde A., Wera S., Beullens M., Torrekens S., Van Leuven F.,
RA   Stalmans W., Bollen M.;
RT   "Molecular cloning of NIPP-1, a nuclear inhibitor of protein
RT   phosphatase-1, reveals homology with polypeptides involved in RNA
RT   processing.";
RL   J. Biol. Chem. 270:28068-28074(1995).
RN   [9]
RP   CHARACTERIZATION (ISOFORM GAMMA).
RX   PubMed=9153239; DOI=10.1074/jbc.272.21.13823;
RA   Claverie-Martin F., Wang M., Cohen S.N.;
RT   "ARD-1 cDNA from human cells encodes a site-specific single-strand
RT   endoribonuclease that functionally resembles Escherichia coli RNase
RT   E.";
RL   J. Biol. Chem. 272:13823-13828(1997).
RN   [10]
RP   RNA-BINDING, CHARACTERIZATION (ISOFORM GAMMA), AND FUNCTION.
RX   PubMed=10432294; DOI=10.1042/0264-6021:3420013;
RA   Jin Q., Beullens M., Jagiello I., Van Eynde A., Vulsteke V.,
RA   Stalmans W., Bollen M.;
RT   "Mapping of the RNA-binding and endoribonuclease domains of NIPP1, a
RT   nuclear targeting subunit of protein phosphatase 1.";
RL   Biochem. J. 342:13-19(1999).
RN   [11]
RP   IDENTIFICATION OF ALTERNATIVE SPLICING IN ISOFORM GAMMA.
RX   PubMed=10564811; DOI=10.1016/S0378-1119(99)00435-7;
RA   Chang A.C.Y., Sohlberg B., Trinkle-Mulcahy L., Claverie-Martin F.,
RA   Cohen P., Cohen S.N.;
RT   "Alternative splicing regulates the production of ARD-1
RT   endoribonuclease and NIPP-1, an inhibitor of protein phosphatase-1, as
RT   isoforms encoded by the same gene.";
RL   Gene 240:45-55(1999).
RN   [12]
RP   FUNCTION, MUTAGENESIS OF TYR-264; TYR-335; THR-346 AND SER-348, AND
RP   PHOSPHORYLATION AT TYR-264 AND TYR-335.
RX   PubMed=11104670; DOI=10.1042/0264-6021:3520651;
RA   Beullens M., Vulsteke V., Van Eynde A., Jagiello I., Stalmans W.,
RA   Bollen M.;
RT   "The C-terminus of NIPP1 (nuclear inhibitor of protein phosphatase-1)
RT   contains a novel binding site for protein phosphatase-1 that is
RT   controlled by tyrosine phosphorylation and RNA binding.";
RL   Biochem. J. 352:651-658(2000).
RN   [13]
RP   INTERACTION WITH CDC5L, SUBCELLULAR LOCATION, MUTAGENESIS OF
RP   68-SER--HIS-71, AND FUNCTION.
RX   PubMed=10827081; DOI=10.1074/jbc.M001676200;
RA   Boudrez A., Beullens M., Groenen P.M.A., Van Eynde A., Vulsteke V.,
RA   Jagiello I., Murray M., Krainer A.R., Stalmans W., Bollen M.;
RT   "NIPP1-mediated interaction of protein phosphatase-1 with CDC5L, a
RT   regulator of pre-mRNA splicing and mitotic entry.";
RL   J. Biol. Chem. 275:25411-25417(2000).
RN   [14]
RP   NUCLEAR LOCALIZATION SIGNALS, MUTAGENESIS OF 68-SER--HIS-71;
RP   195-LYS--LYS-197; SER-199; VAL-201; PHE-203; SER-204 AND
RP   234-LYS--ARG-237, AND SUBCELLULAR LOCATION.
RX   PubMed=11034904;
RA   Jagiello I., Van Eynde A., Vulsteke V., Beullens M., Boudrez A.,
RA   Keppens S., Stalmans W., Bollen M.;
RT   "Nuclear and subnuclear targeting sequences of the protein
RT   phosphatase-1 regulator NIPP1.";
RL   J. Cell Sci. 113:3761-3768(2000).
RN   [15]
RP   SUBCELLULAR LOCATION, INTERACTION WITH PPP1CA AND PPP1CC, AND
RP   MUTAGENESIS OF VAL-201 AND PHE-203.
RX   PubMed=11739654;
RA   Trinkle-Mulcahy L., Sleeman J.E., Lamond A.I.;
RT   "Dynamic targeting of protein phosphatase 1 within the nuclei of
RT   living mammalian cells.";
RL   J. Cell Sci. 114:4219-4228(2001).
RN   [16]
RP   IDENTIFICATION AS PART OF THE SPLICEOSOME, AND FUNCTION.
RX   PubMed=11909864; DOI=10.1074/jbc.M200847200;
RA   Beullens M., Bollen M.;
RT   "The protein phosphatase-1 regulator NIPP1 is also a splicing factor
RT   involved in a late step of spliceosome assembly.";
RL   J. Biol. Chem. 277:19855-19860(2002).
RN   [17]
RP   INTERACTION WITH SF3B1, AND MUTAGENESIS OF 68-SER--HIS-71.
RX   PubMed=12105215; DOI=10.1074/jbc.M204427200;
RA   Boudrez A., Beullens M., Waelkens E., Stalmans W., Bollen M.;
RT   "Phosphorylation-dependent interaction between the splicing factors
RT   SAP155 and NIPP1.";
RL   J. Biol. Chem. 277:31834-31841(2002).
RN   [18]
RP   DNA-BINDING, INTERACTION WITH EED, IDENTIFICATION IN A COMPLEX WITH
RP   EED; HDAC2 AND PP1, MUTAGENESIS OF 68-SER--HIS-71; 193-LYS--LYS-197;
RP   SER-199; VAL-201; PHE-203 AND SER-204, AND FUNCTION.
RX   PubMed=12788942; DOI=10.1074/jbc.M302273200;
RA   Jin Q., van Eynde A., Beullens M., Roy N., Thiel G., Stalmans W.,
RA   Bollen M.;
RT   "The protein phosphatase-1 (PP1) regulator, nuclear inhibitor of PP1
RT   (NIPP1), interacts with the polycomb group protein, embryonic ectoderm
RT   development (EED), and functions as a transcriptional repressor.";
RL   J. Biol. Chem. 278:30677-30685(2003).
RN   [19]
RP   INTERACTION WITH MELK, AND MUTAGENESIS OF 68-SER--HIS-71.
RX   PubMed=14699119; DOI=10.1074/jbc.M311466200;
RA   Vulsteke V., Beullens M., Boudrez A., Keppens S., Van Eynde A.,
RA   Rider M.H., Stalmans W., Bollen M.;
RT   "Inhibition of spliceosome assembly by the cell cycle-regulated
RT   protein kinase MELK and involvement of splicing factor NIPP1.";
RL   J. Biol. Chem. 279:8642-8647(2004).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [21]
RP   INTERACTION WITH PPP1CA; PPP1CB AND PPP1CC.
RX   PubMed=20516061; DOI=10.1074/jbc.M110.109801;
RA   Lee J.H., You J., Dobrota E., Skalnik D.G.;
RT   "Identification and characterization of a novel human PP1 phosphatase
RT   complex.";
RL   J. Biol. Chem. 285:24466-24476(2010).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
CC   -!- FUNCTION: Inhibitor subunit of the major nuclear protein
CC       phosphatase-1 (PP-1). It has RNA-binding activity but does not
CC       cleave RNA and may target PP-1 to RNA-associated substrates. May
CC       also be involved in pre-mRNA splicing. Binds DNA and might act as
CC       a transcriptional repressor. Seems to be required for cell
CC       proliferation.
CC   -!- FUNCTION: Isoform Gamma is a site-specific single-strand
CC       endoribonuclease that cleaves single strand RNA 3' to purines and
CC       pyrimidines in A+U-rich regions. It generates 5'-phosphate termini
CC       at the site of cleavage. This isoform does not inhibit PP-1. May
CC       be implicated in mRNA splicing.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC       Note=Endoribonuclease function is magnesium-dependent.;
CC   -!- SUBUNIT: Interacts with phosphorylated CDC5L, SF3B1 and MELK.
CC       Interacts with EED, in a nucleic acid-stimulated manner. Part of a
CC       complex consisting of PPP1R8, EED, HDAC2 and PP-1. Part of the
CC       spliceosome. Interacts with PPP1CA, PPP1CB and PPP1CC.
CC       {ECO:0000269|PubMed:10827081, ECO:0000269|PubMed:11739654,
CC       ECO:0000269|PubMed:12105215, ECO:0000269|PubMed:12788942,
CC       ECO:0000269|PubMed:14699119, ECO:0000269|PubMed:20516061}.
CC   -!- INTERACTION:
CC       Q92624:APPBP2; NbExp=3; IntAct=EBI-716633, EBI-743771;
CC       P62136:PPP1CA; NbExp=3; IntAct=EBI-716633, EBI-357253;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Nucleus speckle. Note=Primarily,
CC       but not exclusively, nuclear.
CC   -!- SUBCELLULAR LOCATION: Isoform Gamma: Cytoplasm. Note=Found mainly
CC       in the cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=Alpha;
CC         IsoId=Q12972-1; Sequence=Displayed;
CC       Name=Beta; Synonyms=Delta;
CC         IsoId=Q12972-2; Sequence=VSP_005119;
CC       Name=Gamma; Synonyms=ARD-1;
CC         IsoId=Q12972-3; Sequence=VSP_005120;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed, with highest levels in
CC       heart and skeletal muscle, followed by brain, placenta, lung,
CC       liver and pancreas. Less abundant in kidney. The concentration and
CC       ratio between isoforms is cell-type dependent. Isoform Alpha
CC       (>90%) and isoform Beta were found in brain, heart and kidney.
CC       Isoform Gamma is mainly found in B-cells and T-lymphocytes, and
CC       has been found in 293 embryonic kidney cells.
CC       {ECO:0000269|PubMed:10103062, ECO:0000269|PubMed:7499293}.
CC   -!- DOMAIN: Has a basic N- and C-terminal and an acidic central
CC       domain.
CC   -!- DOMAIN: The FHA domain mediates interactions with threonine-
CC       phosphorylated MELK. {ECO:0000250}.
CC   -!- PTM: May be inactivated by phosphorylation on Ser-199 or Ser-204
CC       (By similarity). Phosphorylated by Lyn in vitro on Tyr-264, and
CC       also on Tyr-335 in the presence of RNA. {ECO:0000250,
CC       ECO:0000269|PubMed:11104670}.
CC   -!- MISCELLANEOUS: A synthetic peptide, NIPP-1(330-351), is able to
CC       inhibit PP-1. Phosphorylation of Tyr-335 reduces PP-1 inhibition,
CC       whereas phosphorylation of Thr-346 or Ser-348 has no effect.
CC   -!- SIMILARITY: Contains 1 FHA domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00086}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PPP1R8ID41811ch1p35.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U14575; AAA64749.1; -; mRNA.
DR   EMBL; AF061958; AAD31541.1; -; mRNA.
DR   EMBL; AF061959; AAD31542.1; -; mRNA.
DR   EMBL; AF064757; AAD24669.1; -; Genomic_DNA.
DR   EMBL; AF064751; AAD24669.1; JOINED; Genomic_DNA.
DR   EMBL; AF064752; AAD24669.1; JOINED; Genomic_DNA.
DR   EMBL; AF064753; AAD24669.1; JOINED; Genomic_DNA.
DR   EMBL; AF064754; AAD24669.1; JOINED; Genomic_DNA.
DR   EMBL; AF064755; AAD24669.1; JOINED; Genomic_DNA.
DR   EMBL; AF064756; AAD24669.1; JOINED; Genomic_DNA.
DR   EMBL; AF064757; AAD24670.1; -; Genomic_DNA.
DR   EMBL; AF064754; AAD24670.1; JOINED; Genomic_DNA.
DR   EMBL; AF064755; AAD24670.1; JOINED; Genomic_DNA.
DR   EMBL; AF064756; AAD24670.1; JOINED; Genomic_DNA.
DR   EMBL; AF126488; AAD22486.1; -; mRNA.
DR   EMBL; AK292077; BAF84766.1; -; mRNA.
DR   EMBL; AL020997; CAI20576.1; -; Genomic_DNA.
DR   EMBL; AL109927; CAI20576.1; JOINED; Genomic_DNA.
DR   EMBL; AL020997; CAI20577.1; -; Genomic_DNA.
DR   EMBL; AL109927; CAI20577.1; JOINED; Genomic_DNA.
DR   EMBL; AL020997; CAI20578.1; -; Genomic_DNA.
DR   EMBL; AL109927; CAI20578.1; JOINED; Genomic_DNA.
DR   EMBL; AL109927; CAI21779.1; -; Genomic_DNA.
DR   EMBL; AL020997; CAI21779.1; JOINED; Genomic_DNA.
DR   EMBL; AL109927; CAI21780.1; -; Genomic_DNA.
DR   EMBL; AL020997; CAI21780.1; JOINED; Genomic_DNA.
DR   EMBL; AL109927; CAI21781.1; -; Genomic_DNA.
DR   EMBL; AL020997; CAI21781.1; JOINED; Genomic_DNA.
DR   EMBL; CH471059; EAX07731.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX07732.1; -; Genomic_DNA.
DR   EMBL; BC001597; AAH01597.1; -; mRNA.
DR   EMBL; BC013360; AAH13360.1; -; mRNA.
DR   CCDS; CCDS311.1; -. [Q12972-1]
DR   CCDS; CCDS312.1; -. [Q12972-2]
DR   CCDS; CCDS313.1; -. [Q12972-3]
DR   PIR; I38856; I38856.
DR   RefSeq; NP_002704.1; NM_002713.3. [Q12972-3]
DR   RefSeq; NP_054829.2; NM_014110.4. [Q12972-1]
DR   RefSeq; NP_612568.1; NM_138558.2. [Q12972-2]
DR   UniGene; Hs.533474; -.
DR   PDB; 3V4Y; X-ray; 2.10 A; B/D/F/H=158-216.
DR   PDBsum; 3V4Y; -.
DR   ProteinModelPortal; Q12972; -.
DR   SMR; Q12972; 1-132, 158-212.
DR   BioGrid; 111503; 30.
DR   DIP; DIP-40815N; -.
DR   IntAct; Q12972; 17.
DR   MINT; MINT-133673; -.
DR   STRING; 9606.ENSP00000311677; -.
DR   PhosphoSite; Q12972; -.
DR   BioMuta; PPP1R8; -.
DR   DMDM; 19863082; -.
DR   MaxQB; Q12972; -.
DR   PaxDb; Q12972; -.
DR   PeptideAtlas; Q12972; -.
DR   PRIDE; Q12972; -.
DR   DNASU; 5511; -.
DR   Ensembl; ENST00000311772; ENSP00000311677; ENSG00000117751.
DR   Ensembl; ENST00000373931; ENSP00000363042; ENSG00000117751. [Q12972-2]
DR   GeneID; 5511; -.
DR   KEGG; hsa:5511; -.
DR   UCSC; uc001bov.2; human. [Q12972-1]
DR   CTD; 5511; -.
DR   GeneCards; GC01P028157; -.
DR   HGNC; HGNC:9296; PPP1R8.
DR   HPA; HPA027406; -.
DR   HPA; HPA027417; -.
DR   HPA; HPA027452; -.
DR   MIM; 602636; gene.
DR   neXtProt; NX_Q12972; -.
DR   PharmGKB; PA33659; -.
DR   eggNOG; NOG275265; -.
DR   GeneTree; ENSGT00730000110659; -.
DR   HOGENOM; HOG000231315; -.
DR   HOVERGEN; HBG053645; -.
DR   InParanoid; Q12972; -.
DR   KO; K13216; -.
DR   OMA; PVKKKRM; -.
DR   OrthoDB; EOG7PS1FR; -.
DR   PhylomeDB; Q12972; -.
DR   TreeFam; TF105539; -.
DR   ChiTaRS; PPP1R8; human.
DR   GeneWiki; PPP1R8; -.
DR   GenomeRNAi; 5511; -.
DR   NextBio; 21316; -.
DR   PRO; PR:Q12972; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; Q12972; -.
DR   CleanEx; HS_PPP1R8; -.
DR   ExpressionAtlas; Q12972; baseline and differential.
DR   Genevisible; Q12972; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0016607; C:nuclear speck; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; TAS:ProtInc.
DR   GO; GO:0005681; C:spliceosomal complex; IEA:UniProtKB-KW.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0004519; F:endonuclease activity; IEA:UniProtKB-KW.
DR   GO; GO:0008599; F:protein phosphatase type 1 regulator activity; IEA:Ensembl.
DR   GO; GO:0004865; F:protein serine/threonine phosphatase inhibitor activity; TAS:ProtInc.
DR   GO; GO:0008995; F:ribonuclease E activity; TAS:ProtInc.
DR   GO; GO:0003723; F:RNA binding; TAS:ProtInc.
DR   GO; GO:0008283; P:cell proliferation; IEA:Ensembl.
DR   GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW.
DR   GO; GO:0043086; P:negative regulation of catalytic activity; TAS:GOC.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0006401; P:RNA catabolic process; TAS:ProtInc.
DR   GO; GO:0090501; P:RNA phosphodiester bond hydrolysis; TAS:GOC.
DR   GO; GO:0008380; P:RNA splicing; IEA:UniProtKB-KW.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.200.20; -; 1.
DR   InterPro; IPR000253; FHA_dom.
DR   InterPro; IPR008984; SMAD_FHA_domain.
DR   Pfam; PF00498; FHA; 1.
DR   SMART; SM00240; FHA; 1.
DR   SUPFAM; SSF49879; SSF49879; 1.
DR   PROSITE; PS50006; FHA_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   DNA-binding; Endonuclease; Hydrolase; Magnesium; mRNA processing;
KW   mRNA splicing; Nuclease; Nucleus; Phosphoprotein;
KW   Protein phosphatase inhibitor; Reference proteome; Repeat; Repressor;
KW   RNA-binding; Spliceosome; Transcription; Transcription regulation.
FT   CHAIN         1    351       Nuclear inhibitor of protein phosphatase
FT                                1.
FT                                /FTId=PRO_0000071505.
FT   DOMAIN       49    101       FHA. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00086}.
FT   REGION        1    142       Interaction with CDC5L, SF3B1 and MELK.
FT   REGION      143    224       Interaction with EED.
FT   REGION      191    200       Involved in PP-1 inhibition.
FT   REGION      200    203       Involved in PP-1 binding.
FT   REGION      310    329       Interaction with EED.
FT   REGION      330    351       RNA-binding.
FT   REGION      331    337       Involved in PP-1 inhibition.
FT   MOTIF       185    209       Nuclear localization signal 1.
FT                                {ECO:0000269|PubMed:11034904}.
FT   MOTIF       210    240       Nuclear localization signal 2.
FT                                {ECO:0000269|PubMed:11034904}.
FT   MOD_RES     161    161       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q28147}.
FT   MOD_RES     178    178       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q28147}.
FT   MOD_RES     199    199       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q28147}.
FT   MOD_RES     264    264       Phosphotyrosine; by LYN; in vitro.
FT                                {ECO:0000269|PubMed:11104670}.
FT   MOD_RES     335    335       Phosphotyrosine.
FT                                {ECO:0000305|PubMed:11104670}.
FT   VAR_SEQ       1    224       Missing (in isoform Gamma).
FT                                {ECO:0000303|PubMed:7524097}.
FT                                /FTId=VSP_005120.
FT   VAR_SEQ       1    142       Missing (in isoform Beta).
FT                                {ECO:0000303|PubMed:10103062,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_005119.
FT   MUTAGEN      68     71       SRVH->AAAA: Abolishes interaction with
FT                                CDC5L, SF3B1 and MELK, and localization
FT                                in nuclear speckles. No effect on
FT                                repressor activity.
FT                                {ECO:0000269|PubMed:10827081,
FT                                ECO:0000269|PubMed:11034904,
FT                                ECO:0000269|PubMed:12105215,
FT                                ECO:0000269|PubMed:12788942,
FT                                ECO:0000269|PubMed:14699119}.
FT   MUTAGEN     193    197       KRKRK->AAAAA: No effect on interaction
FT                                with EED. {ECO:0000269|PubMed:12788942}.
FT   MUTAGEN     195    197       KRK->AAA: Abolishes nuclear import; when
FT                                associated with A-234--237-A.
FT                                {ECO:0000269|PubMed:11034904}.
FT   MUTAGEN     199    199       S->A,D: No change in subcellular
FT                                location, no effect on interaction with
FT                                EED or repressor activity; when
FT                                associated with A-204 or D-204.
FT                                {ECO:0000269|PubMed:11034904,
FT                                ECO:0000269|PubMed:12788942}.
FT   MUTAGEN     201    201       V->A: Reduces PP-1 binding, no effect on
FT                                subcellular location or repressor
FT                                activity and prevents retargeting of
FT                                PPP1CA and PPP1CC to nuclear speckles;
FT                                when associated with A-203.
FT                                {ECO:0000269|PubMed:11034904,
FT                                ECO:0000269|PubMed:11739654,
FT                                ECO:0000269|PubMed:12788942}.
FT   MUTAGEN     203    203       F->A: Reduces PP-1 binding, no effect on
FT                                subcellular location or repressor
FT                                activity and prevents retargeting of
FT                                PPP1CA and PPP1CC to nuclear speckles;
FT                                when associated with A-201.
FT                                {ECO:0000269|PubMed:11034904,
FT                                ECO:0000269|PubMed:11739654,
FT                                ECO:0000269|PubMed:12788942}.
FT   MUTAGEN     204    204       S->A,D: No change in subcellular
FT                                location, no effect on interaction with
FT                                EED or repressor activity; when
FT                                associated with A-199 or D-199.
FT                                {ECO:0000269|PubMed:11034904,
FT                                ECO:0000269|PubMed:12788942}.
FT   MUTAGEN     234    237       KKKR->AAAA: Abolishes nuclear import;
FT                                when associated with A-195-197-A.
FT                                {ECO:0000269|PubMed:11034904}.
FT   MUTAGEN     264    264       Y->D: Abolishes in vitro phosphorylation
FT                                of isoform gamma by Lyn.
FT                                {ECO:0000269|PubMed:11104670}.
FT   MUTAGEN     335    335       Y->D: Decreases the ability of isoform
FT                                Gamma to bind and inhibit PP-1.
FT                                {ECO:0000269|PubMed:11104670}.
FT   MUTAGEN     346    346       T->D: No effect on the ability of isoform
FT                                Gamma to inhibit PP-1.
FT                                {ECO:0000269|PubMed:11104670}.
FT   MUTAGEN     348    348       S->D: No effect on the ability of isoform
FT                                Gamma to inhibit PP-1.
FT                                {ECO:0000269|PubMed:11104670}.
FT   HELIX       162    174       {ECO:0000244|PDB:3V4Y}.
FT   STRAND      208    210       {ECO:0000244|PDB:3V4Y}.
SQ   SEQUENCE   351 AA;  38479 MW;  0A0E92B033E37641 CRC64;
     MAAAANSGSS LPLFDCPTWA GKPPPGLHLD VVKGDKLIEK LIIDEKKYYL FGRNPDLCDF
     TIDHQSCSRV HAALVYHKHL KRVFLIDLNS THGTFLGHIR LEPHKPQQIP IDSTVSFGAS
     TRAYTLREKP QTLPSAVKGD EKMGGEDDEL KGLLGLPEEE TELDNLTEFN TAHNKRISTL
     TIEEGNLDIQ RPKRKRKNSR VTFSEDDEII NPEDVDPSVG RFRNMVQTAV VPVKKKRVEG
     PGSLGLEESG SRRMQNFAFS GGLYGGLPPT HSEAGSQPHG IHGTALIGGL PMPYPNLAPD
     VDLTPVVPSA VNMNPAPNPA VYNPEAVNEP KKKKYAKEAW PGKKPTPSLL I
//
